Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa

J Clin Invest. 1982 Feb;69(2):303-8. doi: 10.1172/jci110453.

Abstract

The safety and immunogenicity of a high molecular weight polysaccharide from immunotype 1 Pseudomonas aeruginosa were tested in a dose response fashion in adult volunteers. The vaccine lacked toxicity and pyrogenicity for experimental animals. Doses of 50, 75, 150, or 250 microgram were given to groups of individuals as a single dose subcutaneous injection. Doses of 150 and 250 microgram were associated with a significant rise in binding and opsonic antibody at 2 wk postimmunization. Titers remained unchanged for up to 6 mo. The vaccine was almost devoid of toxicity, eliciting no more than a slightly sore and tender arm at the site of injection. High molecular weight polysaccharide antigen appears to induce a good immune response following vaccination that is effective in mediating opsonophagocytic killing of live P. aeruginosa organisms.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antibodies, Bacterial / biosynthesis
  • Antigens, Bacterial / analysis
  • Antigens, Bacterial / immunology
  • Bacterial Vaccines / immunology*
  • Bacterial Vaccines / standards*
  • Bacterial Vaccines / toxicity
  • Guinea Pigs
  • Horseshoe Crabs / immunology
  • Humans
  • Molecular Weight
  • Opsonin Proteins / immunology
  • Polysaccharides, Bacterial / immunology
  • Polysaccharides, Bacterial / standards
  • Pseudomonas aeruginosa / immunology*
  • Serotyping

Substances

  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Vaccines
  • Opsonin Proteins
  • Polysaccharides, Bacterial